Measurement of minimal residual disease (MRD) is one of the best predictors of treatment outcome for leukemia, lymphoma and myeloma.
Two approaches of specific interest due to the innovation they brought in MRD assessment are multi-color flow cytometry (MFC) and genomic approaches such as next-generation sequencing (NGS). Each technique has advantages and disadvantages, and the most appropriate method may be chosen based on tumor load, type of malignancy, presence or absence of disease-specific markers, the technological limit of detection, turn-around time (TAT) requirement, cost and other factors.
This paper explores, in further detail, the current landscape of MRD detection, key considerations for each approach, and current advancements that will contribute to even further improved MRD detection in the future.
Authors:
Franklin Sedarat, M.D. MSc, Director of Hematopathology, Scientific Advisor, Flow Cytometry
Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics
Complete the form below to access this white paper
Related Insights
Reproducibility Challenges in an era of Massive Data
Presented at the MCBIOS & MAQC 2021 Joint Conference
A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency
Presented at the MCBIOS & MAQC 2021 Joint Conference
Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing
Presented at the MCBIOS & MAQC 2021 Joint Conference
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy
Gene expression and analysis for detection of 38 Immune Landscape Signatures
Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials
Genomic technologies that empower and enhance immuno-oncology trials
Laboratory Solutions for Hepatitis B (HBV) Clinical Trials
Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases
Enabling blood sample prep for single cell sequencing in clinical research
The Role of Genomics in Clinical Trials with Patrick Hurban
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use
AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention
